AngioDynamics Will Pay $12.5M To End DOJ's FCA Probe
AngioDynamics Inc. has agreed to pay $12.5 million to settle False Claims Act allegations that it sold an unapproved chemotherapy drug delivery device and touted it as approved, and that it...To view the full article, register now.
Already a subscriber? Click here to view full article